Compare ADMA Biologics Inc (ADMA) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs MobilEye Global Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while MobilEye Global Inc trades at $8.92 (market cap $7.44B). The key difference: MobilEye Global Inc is far larger — about 3.4× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | MBLY | |
|---|---|---|
Market Cap | $2.18B | $7.44B |
Sector | Health | Technology |
52-Week High | $20.38 | $15.54 |
52-Week Low | $7.60 | $6.56 |
Enterprise Value | $2.25B | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Mobileye Global (MBLY) trades at $8.73, up 3.68% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 61.5% buy ratings and an $11.40 consensus target, representing 30.6% upside potential. Recent Q2 2026 earnings beat expectations with $0.19 EPS versus $0.06 estimate, while the company faces leadership transition as founder Amnon Shashua steps down after 27 years.
The investment case balances strong revenue growth and market positioning in autonomous driving technology against significant profitability challenges and leadership uncertainty. While the company benefits from expanding partnerships like the Stellantis ADAS deal, investors must weigh the -201.49% net margin and negative cash flow projections for 2026 against the substantial upside potential indicated by analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
